CAH

Business Context and Reporting Period

Company: Cardinal Health, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Quarter and nine months ended March 31, 1998
Business Overview: The Company operates primarily in wholesale pharmaceutical distribution (91% of revenues) and healthcare services (pharmacy franchising, automation, and management). The period includes the completion of a merger with MediQual Systems, Inc. and ongoing integration of prior acquisitions.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. Cash flow from operating activities was negative $163.5M for the nine months ended March 31, 1998, compared to negative $339.4M in the prior year period.

Material Changes vs. Prior Period

• Revenue Growth: Net revenues increased 20% in Q3 and 15% for the nine-month period compared to the prior year. Approximately 80% of this growth came from existing customers via volume and price increases.
• Margin Compression: Gross margin percentages declined slightly (Q3: 8.26% vs 8.73%; 9M: 8.04% vs 8.12%). This was driven by a higher mix of lower-margin distribution business and competitive pricing pressures in the distribution sector.
• Expense Efficiency: Selling, general, and administrative (SG&A) expenses as a percentage of revenue improved to 4.20% in Q3 (from 4.66% prior year) due to economies of scale and productivity gains.
• Special Charges: The Company recorded $21.2M in merger-related costs and $8.6M in facility closure/severance charges in Q3 1998. These charges reduced net earnings by approximately $23.7M for the quarter.
• Liquidity: Working capital increased to $1.3B, supported by a $477M increase in accounts payable, offsetting a $153M decrease in cash and significant increases in inventory ($722M) and receivables ($139M).

Guidance, Outlook, and Risks

• Bergen Brunswig Merger: A definitive merger agreement exists to acquire Bergen Brunswig Corporation. The transaction is pending a decision on a preliminary injunction sought by the FTC. A court hearing is scheduled for June 10, 1998, with a decision expected by July 1998. The Company estimates total merger-related charges between $100M and $130M (after tax).
• Future Integration Costs: The Company estimates an additional $6.2M (net of tax) in merger integration costs for completed deals (excluding Bergen) in fiscal 1998 and 1999.
• Year 2000 Compliance: Estimated costs for Y2K remediation are approximately $20M. Management believes systems will be compliant in time to avoid operational disruption.
• Accounting Changes: The Company is evaluating industry advice to report bulk deliveries as revenues rather than just service fees. This change is expected to be adopted in the fiscal year ending June 30, 1998.
• Legal Proceedings: The Company is a defendant in consolidated antitrust litigation regarding brand name prescription drugs. Trial is set for September 1998. The Company believes the allegations are without merit.

Investor Verification Checklist

• FTC Merger Ruling: Monitor the outcome of the FTC's preliminary injunction request regarding the Bergen Brunswig merger, expected by July 1998.
• Merger Cost Estimates: Verify the final total of merger-related charges, currently estimated between $100M and $130M after tax.
• Revenue Recognition Policy: Confirm the impact of the potential change in reporting bulk deliveries as revenue on future financial statements.
• Antitrust Litigation: Track the September 1998 trial date for the Brand Name Prescription Drug Litigation and potential liability exposure.
• Cash Flow Management: Review the significant use of cash in operating activities ($163.5M) driven by inventory and receivable build-up to support revenue growth.